Are the immuno-stimulatory properties of lenalidomide extinguished by co-administration of dexamethasone?

Abstract

Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fight against this disease. © 2012 Landes Bioscience.